Introduction
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death around the world, mainly due to its high metastatic rate [
1]. Recently, metabolic reprogramming has been considered an important feature that drives malignant progression of tumors [
2]. In metastatic cancer cells, energy metabolism is altered due to constant exposure to oxidative stress and chronic nutrient and oxygen depletion. To fulfill biosynthetic and redox requirements, cancer cells consume glucose and secrete lactate even when oxygen is available, a phenomenon known as aerobic glycolysis or the “Warburg effect” [
3]. Hypoxia-inducible factor-1α (HIF-1α) is a key transcription factor in the cell response to hypoxic stress. HIF-1α transcribes genes involved in glycolysis, angiogenesis, and cancer metastasis [
4,
5]. During metabolic stress, AMP-activated protein kinase (AMPK) is activated by sensing a decrease in the ratio of ATP to AMP, leading to inhibition of ATP-consuming metabolic pathways and activation of energy-producing pathways [
6]. In addition, adenylate kinases (AKs), which are abundant nucleotide phosphotransferases, catalyze the generation of two molecules of ADP by transferring a phosphate group from one molecule of ATP or GTP to AMP. The main role of AKs is to balance cellular adenine nucleotide composition to maintain energy homeostasis [
7]. However, the link between energy homeostasis and cancer progression has not been clearly elucidated.
Adenylate kinase 4 (AK4) is localized in the mitochondrial matrix [
8] and has been shown to physically bind to mitochondrial ADP/ATP translocase (ANT) as a stress-responsive protein to maintain cell survival [
9]. Moreover, several genomic and proteomic studies have shown that AK4 expression fluctuates under cellular stress conditions [
10‐
13]. Significantly increased AK4 protein levels have been detected during development, in cultured cells exposed to hypoxia and in an animal model of amyotrophic lateral sclerosis [
9,
14‐
16]. Moreover, Lanning et al. showed that silencing of AK4 elevates the cellular ATP level up to 25% and concurrently increases the ADP/ATP ratio, which activates AMPK signaling [
17]. Previously, we identified AK4 as a lung cancer progression marker by assessing the correlation between AK4 levels and clinicopathological features [
18]. However, how AK4-induced metabolic changes may affect cancer progression remains unclear.
Here, we aimed to investigate the impact of AK4 expression on metabolic genes by analyzing lung cancer microarray datasets and decipher the functional consequences on lung cancer metastasis. We found that HIF-1α activity is significantly activated in lung adenocarcinoma patients with an AK4 metabolic gene signature. Overexpression of AK4 shifts metabolism toward aerobic glycolysis and increases the levels of intracellular reactive oxygen species (ROS), which subsequently stabilizes HIF-1α protein and promotes epithelial-to-mesenchymal transition (EMT) in lung cancer cells in a HIF-1α-dependent manner. These findings represent a novel vicious cycle between AK4 and HIF-1α in response to hypoxic stress during lung cancer progression and highlight the therapeutic opportunity of targeting the AK4-HIF-1α axis in NSCLC.
Materials and methods
Specimens
Clinical non-small cell lung cancer (NSCLC) samples were collected with IRB approval (KMUHIRB-E(I)-20160099) from the Kaohsiung Medical University Hospital and were fixed in formalin and embedded in paraffin before being archived. The archived specimens, with follow-up times up to 200 months, were used for immunohistochemical staining. The histologic diagnosis was made according to the World Health Organization (WHO) classification guidelines for lung cancer. The pathological diagnosis of tumor size, local invasion, lymph node involvement, distal metastasis, and final disease stage were determined according to the American Joint Committee on Cancer (AJCC) TNM classification of lung cancer.
Tissue microarray and immunohistochemical staining
Representative 1-mm-diameter cores from each tumor sample were selected by matching histology from original hematoxylin and eosin (H&E)-stained slides, and the histopathologic diagnosis of all samples was reviewed and confirmed by pathologists. IHC staining was performed using an automated immunostainer (Ventana Discovery XT autostainer, Ventana, USA) with a 30-min heat-induced antigen retrieval procedure in TRIS-EDTA buffer. Protein expression was visualized using a 3,3′-diaminobenzidine (DAB) peroxidase substrate kit (Ventana, USA). The following antibodies were used to detect AK4, HIF-1α, E-cadherin, and pimonidazole in tissues: AK4 (Genetex, 1:200), HIF-1α (Cell Signaling, 1:100), E-cadherin (Cell Signaling, 1:100), and pimonidazole (Hypoxyprobe, INC).
Histology and IHC staining interpretation
The IHC staining results were assessed and scored independently by two pathologists who were blinded to the patient clinical outcomes. A consensus decision was made when there was an interobserver discrepancy. For scoring, both intensity and percentage of protein expression were recorded. The staining intensity was scored as follows: 0, no staining; 1+, weak staining; 2+, moderate staining; 3+, strong staining. The extent of staining was further divided into two groups according to 25% of tumor cells with staining. A high IHC expression level was defined as a staining intensity of 2+ or 3+ in over 25% of tumor cells.
Microarray data analysis
The raw intensities of AK4 overexpression in CL1-0 cells (GSE37903) and lung adenocarcinoma patient datasets (GSE31210) were normalized by robust multichip analysis (RMA) using GeneSpring GX11 (Agilent Technologies). AK4-associated gene signatures were identified by calculating the Pearson correlation coefficient between AK4 expression and each coding gene and ranked according to their correlation coefficient to AK4 expression. After applying a Pearson correlation coefficient of ± 0.3 as a threshold, the AK4 metabolic gene signature was identified by selecting genes with enzyme or transporter annotations. Next, gene set enrichment analysis (GSEA) was performed to rank the probes and analyze gene set enrichment using c2.all.v5.1.symbols.gmt [curated] or c2.cp.kegg.v5.1.symbols.gmt [curated] gene sets as a backend database (
http://www.broadinstitute.org/gsea).
P values less than 0.05 and FDRs less than 25% were considered to indicate significant enrichment.
The activation or inhibition status of upstream regulators in the AK4 metabolic gene signature was predicted using IPA Upstream Regulator Analysis (Ingenuity Systems,
http://www.ingenuity.com), and the calculated
z scores can reflect the overall activation state of the regulator (< 0: inhibited, > 0: activated). In practice, a
z score of more than 2 or less than − 2 can be considered significant activation or inhibition, respectively.
Cell lines
The human lung adenocarcinoma cell lines H1355, PC9, H358, H928, CL1-0 CL1-1, CL1-3, and CL1-5 and squamous cell carcinoma cell lines H157 and H520 were maintained in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS). Human lung adenocarcinoma cell lines (A549, PC13, and PC14) and large cell carcinoma H1299 cells were grown in DMEM (Invitrogen) containing 10% FBS. All cells were kept under a humidified atmosphere containing 5% CO2 at 37 °C. CL1-0, CL1-1, CL1-3, and CL1-5 cell lines were established by Chu et al. at National Taiwan University Hospital and displayed progressively increased invasiveness, while PC13 and PC14 cell lines were derived from Tokyo National Cancer Centre Hospital. Other lung cancer cell lines (A549, H1355, H358, H928, H520, H157, H460, and H1299) were obtained from American Type Culture Collection.
Lentiviral shRNA and expression vectors
GIPZ Lentiviral AK4 (AK3L1) shRNA and HIF1A shRNA constructs, which carry the puromycin resistance gene and enhanced green fluorescent protein (EGFP), were purchased from Open Biosystems. Lentiviruses were generated by transfecting 293 T cells with the shRNA-expression vector and pMD2.G and pDeltaR8.9 using the calcium phosphate precipitation method. Virus-containing supernatants were collected, titrated, and used to infect cells using 8 μg/mL polybrene. Infected cells were selected using 2 μg/mL puromycin. For expression of AK4, full-length AK4 cDNA was cloned into a pLenti6.3 lentiviral vector (Invitrogen). AK4-expressing cell lines were established by infecting cells with the pLenti6.3-AK4 viruses generated by transfection of 293 T cells with pLenti6.3 AK4, pMD2.G, and pDeltaR8.91. Cells were then selected in 5 μg/mL blasticidin.
Western blot analysis
The following antibodies were used in western blot analyses: anti-AK4 (Genetex, 1:2000), anti-HIF-1α (Cell Signaling, 1:1000), anti-hydroxylated HIF-1α (Cell Signaling, 1:1000), anti-E-cadherin (BD Bioscience, 1:1000), anti-vimentin (Sigma, 1:2000), anti-Snail (Cell Signaling, 1:1000), and anti-α-tubulin (Sigma-Aldrich, 1:5000) antibodies.
Reagent and chemicals
Proscillaridin, ouabain, digitoxigenin, digoxin, withaferin-A, and lanatoside-C were purchased from Sigma-Aldrich (St. Louis, MO). ATP colorimetric assay, glucose colorimetric assay, and lactate colorimetric assay kits were purchased from BioVision (Milpitas, CA). CellROX Deep Red Reagent was purchased from Invitrogen.
Cycloheximide assay
Cells were plated in 6-well plates and treated with cycloheximide (CHX) at a concentration of 50 μg/mL for 24 h. Cells were then exposed to hypoxia for 6 h to stabilize HIF-1α protein and then switched to normoxic conditions. Protein lysates were harvested at 20-min intervals under normoxic conditions.
ATP measurement
Cells were grown in a 6-well plate overnight, and the medium was refreshed with complete medium. After 24 h, a cell pellet was collected, and the amount of ATP was quantified using an ATP colorimetric assay kit (BioVision) according to the manufacturer’s protocol.
Glucose consumption assay
Cells were grown in a 6-well plate overnight, and the medium was refreshed with complete medium. After 24 h, the spent medium was collected, and the amount of glucose was quantified using a glucose colorimetric assay kit (BioVision) according to the manufacturer’s protocol.
Lactate production assay
Cells were grown in a 6-well plate overnight, and the medium was refreshed with complete medium. After 24 h, the spent medium was collected, and the amount of lactate was quantified using a lactate colorimetric assay kit (BioVision) according to the manufacturer’s protocol.
ROS measurement
ROS levels were quantified using CellROX Deep Red Reagent (Invitrogen). Briefly, cells were seeded in a 96-well plate (2000 cells/well) and washed with PBS. Cells were then incubated with 5 μM CellROX for 30 min at 37 °C and stained with DAPI. Intracellular ROS were measured using a fluorescence plate reader at absorption/emission wavelengths of ~ 644/665 nm.
Invasion assay
Polycarbonate filters were coated with human fibronectin on the lower side and Matrigel on the upper side. Medium containing 10% FCS was added to each well of the lower compartment of the chamber. Cells were suspended in serum-free medium containing 0.1% bovine serum albumin and loaded into each well of the upper chamber. After 16 h, cells were fixed with methanol and then stained with Giemsa. Cells that invaded to the lower side of the membrane were counted under a light microscope (× 200, ten random fields in each well). All experiments were performed in quadruplicate.
Animal studies
All animal experiments were conducted according to protocols approved by the Academia Sinica Institutional Animal Care and Unitization Committee. Age-matched NOD-SCID Gamma (NSG) mice (6–8 weeks old) were used to construct xenograft models. For the subcutaneous xenograft model, cells were subcutaneously injected into the flanks of NSG mice at a concentration of 1 × 106 cells in 100 μL of PBS. Tumor volumes were measured weekly for 4 weeks. At the endpoint, mice were intravenously injected with Hypoxyprobe™ (Hypoxyprobe, Inc) solution at a dosage of 60 mg/kg body weight and tumors were removed and analyzed for hypoxic necrosis using immunostaining of pimonidazole adducts in tissues. Slides were digitally scanned using ScanScope AT (Aperio Technologies Inc.). Quantification of hypoxic and non-hypoxic areas in pimonidazole-stained slides was performed using Definiens’ Tissue Studio software (Definiens Inc.). For the orthotopic xenograft model of lung cancer metastasis, 1 × 105 CL1-0 Vec cells, CL1-0 AK4 cells, or A549-GL cells (established by infecting cells with EF1 promoter-driven firefly luciferase viruses and IRES-driven EGFR viruses) were suspended in 10 μl of PBS/Matrigel mixture (1:1) and injected into the left lung of NSG mice (n = 6 per group). Mice from the withaferin-A treatment group were administered 1 mg/kg body weight or 4 mg/kg body weight withaferin-A in 100 μL of PBS three times per week via i.p. injection. Control mice were injected with 100 μL of vehicle PBS containing less than 10% DMSO. Four weeks postinjection, mice were sacrificed, and metastatic liver nodules were counted by gross examination. H&E staining was performed to confirm the histology of metastatic nodules.
Statistical analysis
Statistical analyses were performed using SPSS 17.0 software (SPSS, USA). The correlation between AK4 and HIF-1α expression determined via IHC was assessed using Spearman’s rank correlation analysis. Estimates of survival rates were obtained using the Kaplan-Meier method and compared with a log-rank test. For all analyses, a P value < 0.05 was considered statistically significant. All observations were confirmed in at least three independent experiments. The results are presented as the mean ± SD. We used two-tailed, unpaired Student’s t tests for all pairwise comparisons.
Discussion
Dysregulation of HIF is increasingly recognized as a critical step during cancer progression [
19]. Deletion of
Hif1a has been reported to markedly impair metastasis in a mouse mammary tumor virus (MMTV) promoter-driven polyoma middle T antigen mouse model of breast cancer [
20]. In an orthotopic xenograft model of lung cancer, the HIF-1α antagonist PX-478 effectively inhibits tumor progression [
21]. Here, we identified a novel signaling axis whereby enhanced expression of AK4 exaggerates HIF-1α protein expression, leading to EMT induction in lung cancer. Previous studies have shown that AK4 is one of the hypoxia responsive genes and AK4 is also a transcriptional target of HIF-1α [
22‐
25]. Surprisingly, we found that the presence of AK4 can exert feedback regulation of HIF-1α and this AK4-HIF-1α positive feedback loop operates through elevation of intracellular ROS levels, which stabilize HIF-1α protein and induce EMT.
In lung cancer, both small cell and non–small cell lung cancers express high levels of HIF-1α, but its role as a prognostic factor remains controversial. HIF-1α expression has been reported as a poor prognosis marker in several studies [
26‐
29]. However, some studies reported inconsistent results showing that the predictive power of HIF-1α as a prognosis marker is only marginal [
30‐
32]. In our study, patients with high levels of HIF-1α showed a trend toward poor prognosis compared with those exhibiting low levels of HIF-1α. Furthermore, we found that the combined AK4 and HIF-1α status could significantly augment the prognostic power compared with HIF-1α alone (Fig.
2c). Taken together, our results suggest that AK4 may serve as a critical factor dictating the prognostic power of HIF-1α in lung cancer patients.
It is widely known that HIF-1α regulation mainly occurs at the level of protein stability. Under normoxic conditions, HIF-1α is hydroxylated at two conserved proline residues (P402 and P577) by a family of HIF prolyl hydroxylase enzymes that includes PHD1, PHD2, and PHD3. Hydroxylated HIF-1α is then polyubiquitinated by E3 ubiquitin ligase, leading to proteosomal degradation. In hypoxia, hydroxylation does not occur due to the lack of substrate oxygen for PHDs. Moreover, ROS have been reported to inhibit the activity of PHDs [
33‐
36]. In our study, overexpression of AK4 reduced HIF-1α hydroxylation in the presence of MG132, suggesting that AK4 may stabilize HIF-1α protein by decreasing PHD activity via ROS accumulation. Although the mechanism of AK4-mediated ROS production is unclear, the subcellular localization and physiological function of AK4 may provide a clue to the possible mechanism. AK4 interacts with ANT and voltage-dependent anion channel (VDAC) at the mitochondrial matrix, and their interactions are required for regulation of mitochondria membrane permeability and export of ATP from the mitochondrial matrix to the cytosol in exchange for ADP import from the cytosol to the mitochondrial matrix [
9]. Thus, AK4 may regulate the efflux of ROS generated from the electron transport chain (ETC) to the cytosol by interacting with the ANT/VDAC complex. Our results are consistent with those of other studies suggesting that ROS generated from the ETC could contribute to HIF-1α stabilization by blocking HIF-1α hydroxylation and von Hippel Lindau (pVHL) protein binding [
37‐
39].
Prior studies have reported that hypoxia or overexpression of HIF-1α can induce EMT through direct binding of HIF-1α to the hypoxia response elements (HREs) within the Snail and Twist promoters [
40,
41]. Other EMT regulators, such as Zeb1, Zeb2, and TCF-3, have been reported to be upregulated in pVHL-null renal cell carcinoma in which HIF-1α is constitutively overexpressed [
42]. In addition to binding to the canonical HRE, HIF-1α can also interact with a variety of co-factors to activate EMT-associated genes and diverse gene expression in response to hypoxia [
43,
44].
Tumors rewire metabolism to provide sufficient energy and biosynthetic intermediates to meet the requirements of uncontrolled proliferation and progression. Enhanced glucose metabolism not only produces energy but also provides macromolecular precursors and maintains NADPH homeostasis for cancer cells to withstand oxidative stress [
45]. A recent study suggested that increased ROS production is essential to enable and sustain a metastatic phenotype [
46]. However, large-scale clinical trials using an antioxidant supplement as a preventive and therapeutic anticancer strategy did not show a beneficial effect in cancer patients. In contrast, an antioxidant supplement even increased tumor incidence in a genetically engineered mouse model of lung cancer and melanoma [
47,
48]. One possible explanation for these controversial results is that cancer cells adapt to have a tight redox regulation system that allows them to withstand higher ROS accumulation than normal cells but below a critical cytotoxic threshold. The use of general antioxidants might alleviate circulating tumor cells from oxidative stress and accelerate metastasis development. Therefore, a buildup oxidative stress and being equipped with antioxidant defenses is critical for tumors to metastasize [
49]. Through ingenuity upstream regulator analysis of the AK4 metabolic signature, we also found that NRF2, the master regulator of antioxidant responses, was significantly activated, suggesting that high AK4 expression lung adenocarcinoma patients may be accompanied by NRF2 activation (Fig.
1c). Furthermore, microarray analysis revealed that genes encoding enzymes in the glutathione metabolism pathway were differentially expressed upon AK4 overexpression in CL1-0 cells (Fig.
4b and Additional file
1: Figure S3B). Moreover, in animal studies, we showed that overexpression of AK4 not only protects tumors from hypoxic necrosis but also enhances their ability to metastasize. These data are consistent with the notion that only cancer cells equipped with an enhanced antioxidant defense system are capable of leveraging oxidative stress to promote metastasis. Our findings suggest that overexpression of AK4 may trigger metabolic adaptation toward increased intracellular oxidative stress and antioxidant capacity at the same time and subsequently promote HIF-1α-mediated EMT and metastatic dissemination.
Dysregulation of E-cadherin protein through post-translational glycosylation has been shown to be a critical event during cancer progression [
50]. Specifically, the modification of E-cadherin protein at Asn-554 with β1,6-
N-acetylglucosamin (β1,6GlcNAc)-branched
N-glycan catalyzed by
N-acetylglucosaminyltransferase V (GnT-V) disrupts its cell adhesion function and therefore enhances tumor invasion [
51,
52]. In the AK4 metabolic gene signature, we identified genes encode for enzymes in
N-glycan, mucin type
O-glycan, and glycosaminoglycan biosynthesis pathways were significantly enriched (Fig.
1b). To this end, we also found the expression GnT-V protein was regulated by AK4 under hypoxia in a HIF-1α-dependent manner (Additional file
1: Figure S2A). However, the impact of AK4 expression and/or hypoxia on global glycosylation profile in lung cancer remains to be further elucidated.
Through pharmacogenomics analysis, we identified withaferin-A as a potential inhibitor that reverses the AK4-induced gene signature and acts as a potent anti-metastatic agent in lung cancer. Similar to our findings, Hahm et al. showed that withaferin-A treatment inhibits lung metastasis by suppressing glycolysis in a mouse mammary tumor virus–neu (MMTV-neu) transgenic model, which highlights the therapeutic opportunities for targeting the metabolic vulnerability of tumors [
53].
In conclusion, we suggest that overexpression of AK4 stabilizes HIF-1α protein by increasing intracellular ROS levels and induces EMT in NSCLC. More importantly, pharmacologically reversing the AK4 gene signature (e.g., with withaferin-A) may serve as an effective strategy to treat metastatic lung cancer.